DOCSLIB.ORG

Functional Proteome Analysis of Age Associated Prpc Knockout Mice Liver Along with Regulatory Response of Cytoskeleton Associated Tau Protein and Fatty Liver Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Functional Proteome Analysis of Age Associated Prpc Knockout Mice Liver Along with Regulatory Response of Cytoskeleton Associated Tau Protein and Fatty Liver Disease Functional proteome analysis of age associated PrPC knockout mice liver along with regulatory response of cytoskeleton associated tau protein and fatty liver disease. Dissertation For the award of the degree “Doctor rerum naturalium (Dr. rer. nat.)” in the Molecular Medicine Study Program at the Georg-August-University Göttingen Submitted by Amandeep Singh Arora From SAS Nagar (Punjab - India) Göttingen, 2015 i Members of the Thesis Committee: Supervisor: Name, Institute: Prof. Dr. Mathias Bähr, Department of Neurology, University Medical Center, Georg-August University, Göttingen Second member of the thesis committee: Name, Institute: Prof. Dr. Karsten Hanisch, Department of Neuropathology, University Medical Center, Georg-August University, Göttingen Third member of the thesis committee: Name, Institute: Prof. Dr. Mikael Simons, Max Planck Institute for Experimental Medicine, Göttingen Date of Disputation: 14-04-2015 ii DECLARATION Here I declare that my doctoral thesis entitled “Functional proteome analysis of age associated PrPC knockout mice liver along with regulatory response of cytoskeleton associated tau protein and fatty liver disease” has been written independently with no other sources and aids than quoted. Amandeep Singh Arora Göttingen, January 2015 iii Acknowledgments A long journey of more than three years has been interesting and adventurous but it would not have been possible to complete it without the blessings and support of my father Sr. Parlad singh and my mother Smt. Surinder kaur. So, I dedicate my PhD degree to my parents. Firstly, I would like to thanks my direct supervisor prof. Dr. Inga Zerr for giving me opportunity to do PhD in the prion research group and for her scientific and moral support during failures and successful of experiments. Secondly, I thanks to Dr. Saima Zafar for her support in this challenging project which finally gave an interesting and a new outcome. It was a great experience of learning new innovative techniques like CE and executes new challenging ideas, which had not been possible without the support of Dr. Matthias Schmitz. I thanks to Dr. Franc Llorenz, from whom I learnt how to be more productive and efficient during performing of experiments. It was a great help of Prof. Dr. Sabine Mihm from the department of gastroenterology in analyzing the liver disease samples. I would also like to acknowledge the names of Prof. Dr. kollmar and Dr. Katrin Eckermann for their helping contribution in my PhD project. I thanks to my family of labmates and friends, Waqas, Maria, Mohsin, Nadine, Tobias, Neelam, katrin dittmar, Ulla, Siri and our new Portuguese girls, Susana and Angela for their kind help and support during this journey of up and downs. I specially thanks to the funniest creature of our lab and my friend Thüne for making the cool and easy environment for research over the last year. It was a great experience to learn the lab work by our senior lab technician Barbara and I have no words to thanks for the excellent administrative help that I got from our secretaries, Maja and Jolanthe. It was a great help of all kinds from Dr. Prateek kumar, especially during the challenging phases of PhD. I also thank to my friends Dr. Ashish Arora, Dr. Bharat and Dr. Anirban dutta for helping me in taking the right decisions during this journey. There has been a lot of contributions from the long list of my best friends including Rose, Simar, Ashish Rajput, katharina luellmann, Svetlana, Yves, Ali, Irmi Spiess, Jeoffery, Anurag Sankhayan, Gaurav patharia, Johannes, Ranjai sir, Pantalis, Arpit, Nonu and my brother monu, my cousins, Arun, Dipu and Kittu. iv Table of contents 1 Abstract .............................................................................................................. 1 2 Introduction ........................................................................................................ 3 2.1 PrPC and prion .............................................................................................. 3 2.1 Structural features and expression of PrPC .................................................. 3 2.2 Phenotypic interpretation of PrPC knockout mouse models. ......................... 4 2.3 PrPC function and significance of sequence ................................................. 6 2.4 Role of PrPC in aging and oxidative stress ................................................... 6 2.5 Change in behavioral phenotypes during aging ............................................ 8 2.6 Change in biochemical properties of PrPC in aging ...................................... 8 2.6.1 Glycosylation patterns ............................................................................. 8 2.6.2 Localization ............................................................................................. 9 2.7 Role of PrPC in age related neurodegenerative diseases ............................. 9 2.8 Role of PrPC in peripheral tissues ................................................................. 9 2.8.1 Spleen ................................................................................................... 10 2.8.2 Liver ...................................................................................................... 10 2.8.3 Muscle .................................................................................................. 10 2.8.4 Intestine ................................................................................................ 10 2.9 Liver: A model tissue to study PrPC function ............................................... 11 2.10 PrPC knockout mouse models: Importance of Zurich I ................................ 12 2.11 Proteome/genome wide functional analysis of PrPC ................................... 14 2.12 Hypothesis and objectives ........................................................................... 16 3 Materials and Methods .................................................................................... 17 3.1 Animals ........................................................................................................ 17 3.2 2 Dimensional (D) gel electrophoresis ......................................................... 17 3.2.1 Sample preparation. .............................................................................. 17 3.2.2 2D gel electrophoresis, staining and Image Analysis ............................ 17 3.3 In gel digestion and mass spectrometry identification ................................. 18 3.4 Screening of mass spectrometry data ......................................................... 18 3.5 Western blotting. .......................................................................................... 19 3.5.1 Preparation of mice liver samples ......................................................... 19 v 3.5.2 Liver homogenate ................................................................................. 19 3.6 Immunofluorescence ................................................................................... 20 3.7 Measurement of fat in liver tissue ................................................................ 20 3.7.1 Sudan III staining .................................................................................. 21 3.7.2 Triglyceride content ............................................................................... 21 3.8 Capillary Electrophoresis ............................................................................. 21 3.8.1 Sample preparation and capillary immunoassay ................................... 22 3.8.2 Calculations (Expression of PrPC): ....................................................... 22 3.9 Quantitative Real-Time PCR (qPCR) .......................................................... 23 3.10 IPA Analysis ................................................................................................ 25 4 Results .............................................................................................................. 26 4.1 Age and gender specific PrPC expression in mice liver .............................. 26 4.1.1 mRNA expression of PrPC ................................................................... 26 4.1.2 Protein expression of PrPC................................................................... .27 4.1.3 Analysis of PrPC expression by Capillary electrophoresis (CE) ............ 27 4.1.4 Analysis of PrPC expression by Western blot ....................................... 27 4.2 Age and gender specific differential proteome analysis in PrPC knockout mice liver ............................................................................................................... 29 4.2.1 2D gel electrophoresis .......................................................................... 29 4.3 Bio-informatics based functional network analysis ...................................... 37 4.3.1 IPA analysis (Liver as a reference tissue) ............................................. 38 4.3.1.1 Triglyceride content: .......................................................................... 39 4.3.1.2 Fat globules in PrPC knockout mice liver .......................................... 40 4.3.1.3 Liver pathology: ................................................................................. 40 4.3.2 IPA analysis (Brain as a reference tissue) ............................................ 43 4.3.2.1 Altered Tau/Ptau expression in mice liver by Western blot ................ 44 4.3.2.2 Altered Tau/Ptau expression in mice liver by immunofluorescence ... 45 4.3.2.3 Cyclin
Load more

Recommended publications
  • CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout
    Published OnlineFirst August 16, 2016; DOI: 10.1158/0008-5472.CAN-16-1272 Cancer Tumor and Stem Cell Biology Research CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma Josephine Walton1,2, Julianna Blagih3, Darren Ennis1, Elaine Leung1, Suzanne Dowson1, Malcolm Farquharson1, Laura A. Tookman4, Clare Orange5, Dimitris Athineos3, Susan Mason3, David Stevenson3, Karen Blyth3, Douglas Strathdee3, Frances R. Balkwill2, Karen Vousden3, Michelle Lockley4, and Iain A. McNeish1,4 Abstract – – There is a need for transplantable murine models of ovarian ating novel ID8 derivatives that harbored single (Trp53 / )or – – – – high-grade serous carcinoma (HGSC) with regard to mutations in double (Trp53 / ;Brca2 / ) suppressor gene deletions. In these the human disease to assist investigations of the relationships mutants, loss of p53 alone was sufficient to increase the growth between tumor genotype, chemotherapy response, and immune rate of orthotopic tumors with significant effects observed on the microenvironment. In addressing this need, we performed whole- immune microenvironment. Specifically, p53 loss increased exome sequencing of ID8, the most widely used transplantable expression of the myeloid attractant CCL2 and promoted the model of ovarian cancer, covering 194,000 exomes at a mean infiltration of immunosuppressive myeloid cell populations into – – – – depth of 400Â with 90% exons sequenced >50Â. We found no primary tumors and their ascites. In Trp53 / ;Brca2 / mutant functional mutations in genes characteristic of HGSC (Trp53, cells, we documented a relative increase in sensitivity to the PARP Brca1, Brca2, Nf1, and Rb1), and p53 remained transcriptionally inhibitor rucaparib and slower orthotopic tumor growth – – active. Homologous recombination in ID8 remained intact in compared with Trp53 / cells, with an appearance of intratumoral þ functional assays.
    [Show full text]
  • THE FUTURE of SCREENS from James Stanton a Little Bit About Me
    THE FUTURE OF SCREENS From james stanton A little bit about me. Hi I am James (Mckenzie) Stanton Thinker / Designer / Engineer / Director / Executive / Artist / Human / Practitioner / Gardner / Builder / and much more... Born in Essex, United Kingdom and survived a few hair raising moments and learnt digital from the ground up. Ok enough of the pleasantries I have been working in the design field since 1999 from the Falmouth School of Art and onwards to the RCA, and many companies. Ok. less about me and more about what I have seen… Today we are going to cover - SCREENS CONCEPTS - DIGITAL TRANSFORMATION - WHY ASSETS LIBRARIES - CODE LIBRARIES - COST EFFECTIVE SOLUTION FOR IMPLEMENTATION I know, I know, I know. That's all good and well, but what does this all mean to a company like mine? We are about to see a massive change in consumer behavior so let's get ready. DIGITAL TRANSFORMATION AS A USP Getting this correct will change your company forever. DIGITAL TRANSFORMATION USP-01 Digital transformation (DT) – the use of technology to radically improve performance or reach of enterprises – is becoming a hot topic for companies across the globe. VERY DIGITAL CHANGING NOT VERY DIGITAL DIGITAL TRANSFORMATION USP-02 Companies face common pressures from customers, employees and competitors to begin or speed up their digital transformation. However they are transforming at different paces with different results. VERY DIGITAL CHANGING NOT VERY DIGITAL DIGITAL TRANSFORMATION USP-03 Successful digital transformation comes not from implementing new technologies but from transforming your organisation to take advantage of the possibilities that new technologies provide.
    [Show full text]
  • Meridium V3.6X Open Source Licenses (PDF Format)
    Open Source Components Component Version License License Link Usage Home Page .NET Zip Library Unspecified SharpZipLib GPL License (GPL w/exception) http://www.icsharpcode.net/opensource/sharpziplib/ Dynamic Library http://dotnetziplib.codeplex.com/ 32feet.NET Unspecified Microsoft Public License http://opensource.org/licenses/MS-PL File + Dynamic Library http://32feet.codeplex.com AjaxControlToolkit Unspecified Microsoft Public License http://opensource.org/licenses/MS-PL Dynamic Library http://ajaxcontroltoolkit.codeplex.com/ Android - platform - external - okhttp 4.3_r1 Apache License 2.0 http://www.apache.org/licenses/LICENSE-2.0.html File http://developer.android.com/index.html angleproject Unspecified BSD 3-clause "New" or "Revised" License http://opensource.org/licenses/BSD-3-Clause Dynamic Library http://code.google.com/p/angleproject/ Apache Lucene - Lucene.Net 3.0.3-RC2 Apache License 2.0 http://www.apache.org/licenses/LICENSE-2.0.html Dynamic Library http://lucenenet.apache.org/ AttributeRouting (ASP.NET Web API) 3.5.6 MIT License http://www.opensource.org/licenses/mit-license.php File http://www.nuget.org/packages/AttributeRouting.WebApi AttributeRouting (Self-hosted Web API) 3.5.6 MIT License http://www.opensource.org/licenses/mit-license.php File http://www.nuget.org/packages/AttributeRouting.WebApi.Hosted AttributeRouting.Core 3.5.6 MIT License http://www.opensource.org/licenses/mit-license.php Component http://www.nuget.org/packages/AttributeRouting.Core AttributeRouting.Core.Http 3.5.6 MIT License http://www.opensource.org/licenses/mit-license.php
    [Show full text]
  • Javascript Frameworks for Modern Web Development the Essential Frameworks, Libraries, and Tools to Learn Right Now Second Edition
    JavaScript Frameworks for Modern Web Development The Essential Frameworks, Libraries, and Tools to Learn Right Now Second Edition Sufyan bin Uzayr Nicholas Cloud Tim Ambler JavaScript Frameworks for Modern Web Development Sufyan bin Uzayr Nicholas Cloud Al Manama, United Arab Emirates Florissant, MO, USA Tim Ambler Nashville, TN, USA ISBN-13 (pbk): 978-1-4842-4994-9 ISBN-13 (electronic): 978-1-4842-4995-6 https://doi.org/10.1007/978-1-4842-4995-6 Copyright © 2019 by Sufyan bin Uzayr, Nicholas Cloud, Tim Ambler This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Trademarked names, logos, and images may appear in this book. Rather than use a trademark symbol with every occurrence of a trademarked name, logo, or image we use the names, logos, and images only in an editorial fashion and to the benefit of the trademark owner, with no intention of infringement of the trademark. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made.
    [Show full text]
  • Role of Decay-Accelerating Factor in Regulating Complement Activation on the Erythrocyte Surface As Revealed by Gene Targeting
    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 628–633, January 1999 Immunology Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting XIUJUN SUN*, COLIN D. FUNK*, CHENGJUN DENG*, ARVIND SAHU†,JOHN D. LAMBRIS†, AND WEN-CHAO SONG*‡ *Center for Experimental Therapeutics and Department of Pharmacology and †Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 Edited by Stuart H. Orkin, Harvard Medical School, Boston, MA, and approved December 1, 1998 (received for review July 29, 1998) ABSTRACT Decay-accelerating factor (DAF) is a glyco- paroxysmal nocturnal hemoglobinuria (PNH) syndrome, a sylphosphatidylinositol (GPI)-anchored membrane protein disease characterized by an increased sensitivity of red blood that inhibits both the classical and the alternative pathways of cells to autologous complement-mediated lysis (7, 8). It is now complement activation. DAF has been studied extensively in understood that the fundamental defect in PNH occurs at the humans under two clinical settings: when absent from the stage of GPI anchor biosynthesis as a result of somatic erythrocytes of paroxysmal nocturnal hemoglobinuria (PNH) mutations in the PIG-A gene in hematopoietic stem cells rather patients, who suffer from complement-mediated hemolytic than a defect in the DAF gene per se (9). Thus, DAF and all anemia, and in transgenic pigs expressing human DAF, which other GPI-anchored proteins are absent from the affected have been developed to help overcome complement-mediated blood cells of PNH patients (9). hyperacute rejection in xenotransplantation. Nevertheless, The in vivo function of DAF in regulating complement the exact role of DAF in regulating complement activation in activation on the cell surface, highlighted by its absence from vivo on the cell surface and the species specificity of this the affected erythrocytes of PNH patients, remains an unset- molecule remain to be fully characterized.
    [Show full text]
  • Survival Rates of Homozygotic Tp53 Knockout Rats As a Tool For
    Strzemecki et al. Cellular & Molecular Biology Letters (2017) 22:9 Cellular & Molecular DOI 10.1186/s11658-017-0039-z Biology Letters SHORTREPORT Open Access Survival rates of homozygotic Tp53 knockout rats as a tool for preclinical assessment of cancer prevention and treatment Damian Strzemecki†, Magdalena Guzowska† and Paweł Grieb* * Correspondence: [email protected] Abstract † Equal contributors Tp53 Department of Experimental Background: The gene that encodes tumor protein p53, , is mutated or Pharmacology, Mossakowski silenced in most human cancers and is recognized as one of the most important Medical Research Centre, Polish cancer drivers. Homozygotic Tp53 knockout mice, which develop lethal cancers early Academy of Sciences, 5 Tp Pawińskiego Str., Warsaw 02-106, in their lives, are already used in cancer prevention studies, and now 53 knockout Poland rats have also been generated. This study assessed feasibility of using homozygous Tp53 knockout rats to evaluate the possible outcome of cancer chemoprevention. Methods: A small colony of Tp53 knockout rats with a Wistar strain genetic background was initiated and maintained in the animal house at our institution. Tp53 heterozygotic females were bred with Tp53 homozygous knockout males to obtain a surplus of knockout homozygotes. To evaluate the reproducibility of their lifespan, 4 groups of Tp53 homozygous knockout male rats born during consecutive quarters of the year were kept behind a sanitary barrier in a controlled environment until they reached a moribund state. Their individual lifespan data were used to construct quarterly survival curves. Results: The four consecutive quarterly survival curves were highly reproducible. They were combined into a single “master” curve for use as a reference in intervention studies.
    [Show full text]
  • Choosing the Best Javascript Framework
    Choosing the Best JavaScript Framework Andy Gup, Esri US Raul Jimenez, Esri ES Frameworks, frameworks, … Do I even need a framework?? Has.jsRaphael The Boiler BootstrapLess+ DojoWirefy Foundation 3 SenchaTitan Susy Skeleton Ingrid jQuery Less Phonegap X X 1991 2012 ECMA 5.1 ECMA 2015 June 2011 June 2015 JavaScript Frameworks & Libraries: Timeline MooTools Kendo Polymer 05/2014 script.aculo.us 09/2006 AngularJS UI 06/2005 2009 04/2014 Kartograph Ionic 08/2013 Phonegap jQuery 2013 2009 08/2006 Backbone Ember.js 10/2013 JavaScriptMVC Knockout 12/2011 YUI 05/2008 02/2006 7/2010 CMV 02/2013 Web Bootstrap AppBuilder Titanium Prototype 04/2011 07/2014 12/2008 2005 ExtJS Ractive 12/2007 08/2013 React native jQuery React.js 03/2015 Dojo Mobile 2013 08/2005 10/2010 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Event-driven One-Page Discontinued Hybrid Geospatial Trends: Interest over time 2005 - 2007 2007 - 2012 2004 - 2012 Your Considerations • New project or expanding existing project? • Your project size (small, medium, large)? • Do you have existing build system? • Do you have existing frameworks? • Your teams skill sets? • Your requirements? Learning curve Evaluating a framework • Framework 3rd party sponsorship • Major version changes • Documentation • Stackoverflow questions Evaluating a framework Angular.js Mono Evaluating a framework Latest commit … Oct 6, 2011!!! Evaluating a framework Number of: • Closed issues • Open issues • Open pull requests • Contributors Evaluating a framework • Trendiness (cool factor) vs Stable/Secure
    [Show full text]
  • Technical Expertise
    www.ultantechnologies.com Technical Expertise Subject: Ultan Technologies Technical Expertise Author: Cathal Brady Date Published: 01/03/2016 Version Number: Version 1 www.ultantechnologies.com Contents 1 INTRODUCTION ..................................................................................................................... 1 2 .NET ....................................................................................................................................... 1 3 DATABASES ........................................................................................................................... 2 4 BIG DATA ............................................................................................................................... 2 5 JAVA ...................................................................................................................................... 3 6 PHP, RUBY, PYTHON .............................................................................................................. 3 7 FRONT END............................................................................................................................ 4 8 3RD PARTY INTEGRATION, APIs, PLUGINS ............................................................................. 4 9 CONTINUOUS INTEGRATION / BUILD AUTOMATION / VERSION CONTROL .......................... 4 10 MOBILE DEVELOPMENT ........................................................................................................ 5 11 CRM CUSTOMISATION .........................................................................................................
    [Show full text]
  • Jquery Knockout Interview Questions and Answers Guide
    jQuery Knockout Interview Questions And Answers Guide. Global Guideline. https://www.globalguideline.com/ jQuery Knockout Interview Questions And Answers Global Guideline . COM jQuery Knockout Job Interview Preparation Guide. Question # 1 Explain some features of jQuery Knockout? Answer:- Elegant dependency tracking - automatically updates the right parts of your UI whenever your data model changes. Declarative bindings - a simple and obvious way to connect parts of your UI to your data model. You can construct a complex dynamic UIs easily using arbitrarily nested binding contexts. Trivially extensible - implement custom behaviors as new declarative bindings for easy reuse in just a few lines of code. Read More Answers. Question # 2 Explain some benefits of jQuery Knockout? Answer:- Pure JavaScript library - works with any server or client-side technology Can be added on top of your existing web application without requiring major architectural changes Compact - around 13kb after gzipping Works on any mainstream browser (IE 6+, Firefox 2+, Chrome, Safari, others) Comprehensive suite of specifications (developed BDD-style) means its correct functioning can easily be verified on new browsers and platforms Read More Answers. Question # 3 How to use it jQuery knockout? Answer:- The quickest and most fun way to get started is by working through the interactive tutorials. Read More Answers. Question # 4 Please tell us that is jQuery Knockkout intended to compete with jQuery or Prototype or work with it? Answer:- As you know everyone loves jQuery! It's an outstanding replacement for the clunky, inconsistent DOM API we had to put up with in the past. jQuery is an excellent low-level way to manipulate elements and event handlers in a web page.
    [Show full text]
  • Preview Knockoutjs Tutorial (PDF Version)
    KnockoutJS About the Tutorial KnockoutJS is basically a library written in JavaScript, based on MVVM pattern that helps developers in building rich and responsive websites. KnockoutJS library provides an easy and clean way to handle complex data-driven interfaces. It is independent of any other framework. This tutorial covers most of the topics required for a basic understanding of KnockoutJS and explains its various functionalities. Audience This tutorial is designed for software programmers who want to learn the basics of KnockoutJS and its programming concepts in a simple and easy way. This tutorial will give you enough understanding on the components of KnockoutJS with suitable examples. Prerequisites Before proceeding with this tutorial, you should have a basic understanding of HTML, CSS, JavaScript, Document Object Model (DOM), and any text editor. As we are going to develop web-based application using KnockoutJS, it will be good if you have an understanding on how the Internet and web-based applications work. Copyright & Disclaimer Copyright 2017 by Tutorials Point (I) Pvt. Ltd. All the content and graphics published in this e-book are the property of Tutorials Point (I) Pvt. Ltd. The user of this e-book is prohibited to reuse, retain, copy, distribute or republish any contents or a part of contents of this e-book in any manner without written consent of the publisher. We strive to update the contents of our website and tutorials as timely and as precisely as possible, however, the contents may contain inaccuracies or errors. Tutorials Point (I) Pvt. Ltd. provides no guarantee regarding the accuracy, timeliness or completeness of our website or its contents including this tutorial.
    [Show full text]
  • Hnrnp U Protein Is Required for Normal Pre-Mrna Splicing And
    hnRNP U protein is required for normal pre-mRNA PNAS PLUS splicing and postnatal heart development and function Junqiang Yea, Nadine Beetzb,c, Sean O’Keeffea, Juan Carlos Tapiaa, Lindsey Macphersona, Weisheng V. Chena, Rhonda Bassel-Dubyb, Eric N. Olsonb, and Tom Maniatisa,1 aDepartment of Biochemistry and Molecular Biophysics, Columbia University College of Physicians and Surgeons, New York, NY 10032; bDepartment of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390; and cInstitute of Experimental and Clinical Pharmacology and Toxicology, University of Freiburg, 79104 Freiburg, Germany Contributed by Tom Maniatis, April 30, 2015 (sent for review March 2, 2015; reviewed by Brenton R. Graveley) We report that mice lacking the heterogeneous nuclear ribonucleo- overlap between RBM20 and RBM24 splicing targets, suggesting protein U (hnRNP U) in the heart develop lethal dilated cardiomy- that RBM20 and RBM24 are involved in regulating splicing of opathy and display numerous defects in cardiac pre-mRNA splicing. distinct groups of pre-mRNAs and there is little cross-talk be- Mutant hearts have disorganized cardiomyocytes, impaired con- tween these two splicing factors. tractility, and abnormal excitation–contraction coupling activities. Distinct splicing activities have also been ascribed to general RNA-seq analyses of Hnrnpu mutant hearts revealed extensive de- splicing factors (1). There are two major types of ubiquitously fects in alternative splicing of pre-mRNAs encoding proteins known expressed RBPs: the heterogeneous nuclear ribonucleoproteins to be critical for normal heart development and function, including (hnRNPs) and serine/arginine (SR)-rich proteins. hnRNPs and SR Titin and calcium/calmodulin-dependent protein kinase II delta proteins are generally believed to play opposite roles in splicing: (Camk2d).
    [Show full text]
  • Breaking XSS Mitigations Via Script Gadgets
    Code-Reuse Attacks for the Web: Breaking XSS mitigations via Script Gadgets Sebastian Lekies (@slekies) Krzysztof Kotowicz (@kkotowicz) Eduardo Vela Nava (@sirdarckcat) Agenda 1. Introduction to XSS and XSS mitigations 2. What are Script Gadgets? 3. Script Gadgets in popular JavaScript libraries 4. Script Gadgets in real world applications 5. Fixing (DOM) XSS in the Web plattform 6. Summary & Conclusion Introduction Cross-Site-Scripting (XSS) primer XSS is a JavaScript injection vulnerability. <?php echo "<h1>Hello " . $_GET['username'] . "</h1>"; ?> username=<script> username=sebastian alert(1)</script> Isn't XSS a solved problem? Google VRP Rewards How do mitigations work? NoScript Filter www.website.com/xss.php?inj=<XSS></XSS> IE/Chrome Filter Warning! <XSS></XSS>GET REMOVE SCRIPT /xss.php?inj=<XSS></XSS> Warning! <XSS></XSS> REMOVE SCRIPT or WAF/ModSecurity BLOCK REQUEST CSP <XSS></XSS> Is <XSS></XSS> Sanitizers allowed? Warning! <XSS></XSS> No BLOCK BLOCK REQUEST Is <XSS></XSS> allowed? No REMOVE Mitigations assume that blocking/removing dangerous tags & attributes stops XSS. Is this true when building an application with a modern JS framework? Modern Applications - Example Any security <div data-role="button" data-text="I am a button"></div> issues in this <script> code? Script Gadget var buttons = $("[data-role=button]"); buttons.html(buttons.attr("data-text")); </script> <div data-role="button" … >I am a button</div> What are Script Gadgets? XSS BEGINS HERE <div data-role="button" data-text="&lt;script&gt;alert(1)&lt;/script>"></div> XSS ENDS HERE <div data-role="button" data-text="I am a button"></div> <script> Script Gadget var buttons = $("[data-role=button]"); buttons.html(buttons.attr("data-text")); </script> <div data-role="button" … ><script>alert(1)</script></div> A Script Gadget is a piece of legitimate JavaScript code that can be triggered via an HTML injection and that upgrades otherwise benign HTML code to code execution.
    [Show full text]